產(chǎn)品詳情
僅用于工業(yè)應(yīng)用或科學(xué)研究,不可用于人類或動物的臨床診斷或治療,非藥用. Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of Ocrelizumab are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Ocrelizumab is the first monoclonal antibody for secondary primary progressive multiple sclerosis (PPMS)